Investor & Media Relations

We discover and develop medicines to defeat neurodegeneration.

The science is breaking open and the time is right for an ambitious and rigorous effort to address Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.

With a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in meaningfully improving the lives of patients and their families.

Denali Nasdaq

Press Releases

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Jan 13, 2025

Read More
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Jan 08, 2025

Read More
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 06, 2025

Read More


VIEW ALL


Events

VIEW ALL

Corporate Presentation


  • Change

  • Volume

  • Market Cap

  • Today's Open

  • Previous Close

  • Exchange

    NASDAQ

  • Today's High

  • Today's Low

  • 52 Week High

  • 52 Week Low

Minimum 15 minutes delayed. Source: LSEG

Analyst Coverage

View detailed list of firms and analysts.

View Coverage

SEC Filing

View, download, and share all SEC Filing documents.

View Documents

Corporate Governance

View, download, and share Corporate Governance documents.

View Documents

FAQs

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox